BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that has been researched for decades for its potential role in tissue healing, tendon and ligament repair, muscle recovery, and gastrointestinal protection.
Originally characterized by researchers at the University of Zagreb, BPC-157 has become one of the most discussed peptides in preclinical healing research because studies have investigated its effects across many different tissue types — from tendons and muscle to the gut lining.
What Is BPC-157?
BPC-157 is a chain of 15 amino acids (GEPPPGKPADDAGLV, molecular weight ~1419 Da) derived from a protective protein found in human gastric juice.
Unlike some peptides that degrade quickly in stomach acid, BPC-157 was specifically noted by researchers for being stable in human gastric juice, which is part of why it has been studied through multiple routes of administration in animal models, including oral, injected, and topical application.
Research has investigated BPC-157 for its potential effects on tendon and ligament healing, muscle repair, angiogenesis (blood vessel formation), nitric oxide signaling, gastrointestinal protection, and bone healing.
How Does BPC-157 Work?
BPC-157 has been studied for its interaction with several biological pathways involved in tissue repair. Researchers have investigated its relationship with:
- Angiogenesis and VEGF signaling — studies have reported modulated blood vessel formation during healing, associated with vascular endothelial growth factor (VEGF) expression
- The nitric oxide (NO) system — preclinical work has examined BPC-157’s interaction with nitric oxide pathways involved in vascular tone and tissue protection
- Growth hormone receptor expression — cell studies have reported increased growth hormone receptor activity in tendon fibroblasts
- FAK-paxillin signaling — research on tendon cells has investigated this pathway’s role in cell migration during repair
- Growth factor activity — animal studies have examined BPC-157 alongside pathways involving EGF, FGF, and related healing signals
- Inflammatory signaling — preclinical models have studied its effects on inflammatory responses during tissue repair
Key Takeaway: BPC-157 is particularly interesting to researchers because studies have investigated its effects across many tissue types and healing models rather than a single pathway — though nearly all of this work remains preclinical.
Potential Benefits of BPC-157
Tendon & Ligament Research
Tendon and ligament healing is the most extensively studied area of BPC-157 research.
In a widely cited rat study, researchers transected the Achilles tendon and found that BPC-157-treated animals showed improved biomechanical strength, better functional recovery scores, and superior collagen and fibroblast formation compared to controls over a 14-day observation period.
Separate research on ligament injury reported improved healing of transected knee ligaments in rats over a 90-day period, with benefits observed whether the peptide was administered systemically, orally, or applied locally. Cell-culture studies have reported increased tendon fibroblast outgrowth and migration, along with improved cell survival under oxidative stress.
Muscle Injury Research
BPC-157 has been studied in several animal models of muscle damage, including crush injuries and muscle-to-bone detachment.
Researchers reported accelerated muscle fiber regeneration and restoration of myotendinous junctions (where muscle meets tendon) within one to two weeks in treated animals, along with reduced scar tissue formation compared to untreated controls. Some studies also investigated BPC-157 in models where healing was deliberately impaired, such as tissues affected by corticosteroid use.
Gastrointestinal Research
Consistent with its origin as a gastric juice protein fragment, BPC-157 has been studied extensively in gastrointestinal damage models.
Published animal research has reported protective effects in models of ethanol-induced gastric lesions, NSAID-related intestinal damage, inflammatory bowel conditions, and healing of gastrointestinal fistulas and anastomoses. A 2018 review by the originating research group surveyed this preclinical literature and described BPC-157 as a proposed “cytoprotective mediator” in gut healing models.
Bone & Other Preclinical Research
Animal studies have also investigated BPC-157 in bone healing models, including delayed bone unions, where researchers reported enhanced bone formation and consolidation. Smaller bodies of preclinical literature have examined neurological models, vascular systems, and corneal healing — all in animals, and all preliminary.
It is important to distinguish these laboratory and animal findings from demonstrated clinical outcomes in humans.
BPC-157 vs. Other Peptides
BPC-157 has a different research profile from peptides such as GHK-Cu, TB-500, and KPV, which are researched for different biological pathways.
GHK-Cu is a naturally occurring copper-binding peptide studied primarily for skin biology, collagen-related processes, and tissue remodeling.
TB-500 (a fragment of thymosin beta-4) has been studied in animal models for cell migration and tissue repair, with a research focus overlapping BPC-157’s in musculoskeletal healing.
KPV is a tripeptide fragment studied mainly for its relationship with inflammatory signaling pathways.
BPC-157’s research is more closely associated with:
Tendon → Ligament → Muscle → Gastrointestinal Healing
This makes BPC-157 particularly relevant to research involving musculoskeletal repair and gut-tissue protection models.
Regulatory Status
BPC-157’s regulatory position has shifted in recent years, and it is worth stating plainly:
- BPC-157 is not FDA approved for any indication, and no BPC-157 drug product has been approved anywhere as a medicine.
- In September 2023, BPC-157 was classified as an FDA 503A Category 2 bulk drug substance, meaning it was prohibited for use in compounding by licensed U.S. pharmacies.
- In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157 — along with five other peptides — to the 503A Bulks List. This was an advisory recommendation only: the FDA retains final authority, formal rulemaking is still required, and the vote does not constitute FDA approval or an authorization to compound. As of this writing, BPC-157 remains not legal to compound.
- The U.S. Anti-Doping Agency (USADA) lists BPC-157 as prohibited for athletes due to the lack of safety data.
Regulatory developments do not change the underlying evidence base: human clinical data remains extremely limited.
What Does the Research Say?
The scientific literature provides a basis for continued research into BPC-157, particularly in tendon, ligament, muscle, and gastrointestinal healing models.
However, the gap between the preclinical literature and human evidence is unusually wide. A 2025 systematic review screened over 500 papers and included 36 studies published between 1993 and 2024: 35 were preclinical (animal or cell studies) and only one involved humans — a small, uncontrolled retrospective chart review of 12 patients with chronic knee pain who received injections at a single clinic, with no control group and no blinding.
No randomized controlled human trial of BPC-157 has been completed. No human dosing has been established. No published human safety data beyond a small pilot report exists.
Promising animal research is not the same as proven medical outcomes, and the current enthusiasm around BPC-157 runs well ahead of what the human evidence supports.
Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It has been researched primarily in animal models for tendon, ligament, muscle, and gastrointestinal healing.
What does the research show?
Animal and cell studies have reported improved tendon and ligament healing, accelerated muscle repair, modulated angiogenesis, and gastrointestinal protection. However, a 2025 systematic review found that 35 of 36 published studies were preclinical, with only one small uncontrolled human report — so human evidence remains insufficient to draw conclusions.
Is BPC-157 FDA approved?
No. BPC-157 is not FDA approved for any indication. In July 2026, an FDA advisory committee voted to recommend it for the 503A compounding bulks list, but that recommendation is advisory only — it is not an approval, and formal FDA rulemaking is still required.
Is BPC-157 naturally occurring?
BPC-157 as studied is a synthetic peptide. Its amino acid sequence is derived from a naturally occurring protective protein found in human gastric juice, but the compound used in research is produced synthetically.
Why is BPC-157 prohibited in sports?
The U.S. Anti-Doping Agency lists BPC-157 as a prohibited substance for athletes, citing the lack of human safety data and its experimental status.
Has BPC-157 been tested in humans?
Barely. The published human record consists of one small 2021 retrospective chart review (12 patients, no control group) and a 2025 pilot report of intravenous administration in two healthy adults. A Phase 1 safety and pharmacokinetics trial is listed on ClinicalTrials.gov, but no controlled efficacy trial has been completed.
The Bottom Line
BPC-157 is one of the most extensively studied peptides in preclinical healing research, with decades of animal studies investigating its potential role in tendon and ligament repair, muscle recovery, angiogenesis, and gastrointestinal protection.
The animal research is remarkably consistent — but it is still animal research. With only one small uncontrolled human report published and no completed clinical trials, the evidence does not support conclusions about safety or effectiveness in people.
For researchers interested in tissue-repair biology, BPC-157 remains an important and actively discussed area of ongoing preclinical research.
Explore BPC-157
Learn more about BPC-157 and explore our research-focused BPC-157 peptide at Vonox Labs.
Research. Test. Learn.
Ver materiales de investigación: Tienda VONOX Labs
Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.
Scientific References
- Starešinić M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003.
- Chang CH, et al. (Increased ex vivo outgrowth of tendon explants, tendon fibroblast migration via FAK-paxillin signaling, and cell survival under oxidative stress.) J Orthop Res. 2011.
- Chang CH, et al. (Increased growth hormone receptor expression and activity in cultured tendon fibroblasts.) 2014.
- Cerovecki T, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. (Medial collateral ligament transection model; systemic, oral, and local administration.) 2010.
- Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018. PMID 29879879.
- Vasireddi H, Hahamyan A, Salata M, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. (36 studies, 1993–2024; 35 preclinical, 1 uncontrolled human chart review; no completed controlled human efficacy trials.) 2025. PMC12313605.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. (Retrospective chart review, 12 BPC-157-only patients, no control group.)
Leave a Reply